real-time news and commentary for investors
Tuesday, Feb 5
Idenix (IDIX -0.6%) regains some of yesterday's post-session dip, but still trails the overall...
Idenix (IDIX -0.6%) regains some of yesterday's post-session dip, but still trails the overall market after saying that it's discontinuing its clinical development program for two of its investigational hepatitis C drugs, after the FDA said the treatments would remain on clinical hold. The hold is related to the regulator's heart-safety concerns about rival Bristol-Myers Squibb's (BMY) BMS-986094, a treatment for the liver disease which belongs to the same class of drugs known as nucleotide polymerase inhibitors.